This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Donckier, J. E. Articles by Ketelslegers, J. M. Search for Related Content PubMed PubMed Citation Articles by Donckier, J. E. Articles by Ketelslegers, J. M.

Circulation, Vol 84, 2476-2484, Copyright © 1991 by American Heart Association

ARTICLES

Cardiovascular and endocrine effects of endothelin-1 at pathophysiological and pharmacological plasma concentrations in conscious dogs

JE Donckier, C Hanet, A Berbinschi, L Galanti, A Robert, H Van Mechelen, H Pouleur and JM Ketelslegers
Division of Endocrinology, University Hospital UCL of Mont-Godinne, Yvoir, Belgium.

BACKGROUND. Increased plasma concentrations of endothelin-1, a potent vasoconstrictor produced by the endothelium, have been reported in various pathological conditions. This study was conducted to evaluate effects of endothelin-1 at pathophysiological and pharmacological plasma concentrations. METHODS AND RESULTS. Endothelin-1 was infused at increasing doses (2.5, 5, 10, and 20 ng/kg.min for 1 hour each) in nine conscious dogs. During endothelin-1 infusion, plasma endothelin-1 rose from a basal value of 1.8 +/- 0.4 pmol/l to 5.8 +/- 1.1 (pathophysiological), 20.8 +/- 3.9 (pathophysiological), 85.4 +/- 18.9 (pharmacological), and 311.4 +/- 55.7 (pharmacological) pmol/l at each dose, respectively. Heart rate increased at 2.5 ng/kg.min (from 129 +/- 7 to 146 +/- 12 beats/min) but decreased at 20 ng/kg.min (97 +/- 7 beats/min) (p less than 0.001). Such a biphasic response was also observed for peak (+)dP/dt and (dP/dt)/DP40 (p less than 0.005). Left ventricular systolic pressures, mean aortic pressure, and left atrial pressure increased over time (p less than 0.05, p less than 0.005, and p less than 0.001, respectively). The time constant of early isovolumic relaxation rose progressively (p less than 0.001). The percent systolic shortening decreased at 10 and 20 ng/kg.min (p less than 0.005). Pressure-segment length loops showed a reduction in systolic shortening associated with an increase in left ventricular systolic pressure at 20 ng/kg.min. Atrial natriuretic factor rose after 5 ng/kg.min from 28.5 +/- 6.5 to 92.0 +/- 18.2 pmol/l (p less than 0.005). Angiotensin II and catecholamines did not change significantly. Serum urea and creatinine rose progressively (p less than 0.05), whereas glucose decreased (p less than 0.05). The above results differed significantly from measurements obtained in a time-control group of six dogs. CONCLUSIONS. A fourfold increase of plasma endothelin-1 obtained after doubling the infusion rate suggests a reduction in endothelin-1 clearance or endothelin-1 endogenous production. The biphasic response of heart rate is consistent with baroreflex-mediated effects resulting from vasodilation at the pathophysiological level and vasoconstriction at the pharmacological level. Hemodynamic data suggest an increase followed by a decrease in contractility at both levels, respectively. Finally, endothelin-1 is a stimulator of atrial natriuretic factor.

This article has been cited by other articles:

				S. Motte, M. Mathieu, S. Brimioulle, A. Pensis, L. Ray, J.-M. Ketelslegers, N. Montano, R. Naeije, P. van de Borne, and K. M. Entee Respiratory-related heart rate variability in progressive experimental heart failure Am J Physiol Heart Circ Physiol, October 1, 2005; 289(4): H1729 - H1735. [Abstract] [Full Text] [PDF]

				M. Okajima, R. Parent, E. Thorin, and M. Lavallee Pathophysiological plasma ET-1 levels antagonize {beta}-adrenergic dilation of coronary resistance vessels in conscious dogs Am J Physiol Heart Circ Physiol, October 1, 2004; 287(4): H1476 - H1483. [Abstract] [Full Text] [PDF]

				L. E. Spieker, G. Noll, F. T. Ruschitzka, and T. F. Luscher Endothelin receptor antagonists in congestive heart failure: a new therapeutic principle for the future? J. Am. Coll. Cardiol., May 1, 2001; 37(6): 1493 - 1505. [Abstract] [Full Text] [PDF]

				P.-E. Massart, J. Donckier, J. Kyselovic, T. Godfraind, G. R. Heyndrickx, and M. Wibo Carvedilol and Lacidipine Prevent Cardiac Hypertrophy and Endothelin-1 Gene Overexpression After Aortic Banding Hypertension, December 1, 1999; 34(6): 1197 - 1201. [Abstract] [Full Text] [PDF]

				S. Battistelli, M. Billi, G. Manasse, A. Vittoria, F. Roviello, and S. Forconi Behavior of Circulating Endothelin-1 in a Group of Patients with Acute Myocardial Infarction Angiology, August 1, 1999; 50(8): 629 - 638. [Abstract] [PDF]

				G. P. Rossi, A. Sacchetto, M. Cesari, and A. C Pessina Interactions between endothelin-1 and the renin-angiotensin-aldosterone system Cardiovasc Res, August 1, 1999; 43(2): 300 - 307. [Abstract] [Full Text] [PDF]

				C. E. King-VanVlack, S. E. Curtis, J. D. Mewburn, S. M. Cain, and C. K. Chapler Endothelial modulation of neural sympathetic vascular tone in canine skeletal muscle J Appl Physiol, October 1, 1998; 85(4): 1362 - 1367. [Abstract] [Full Text] [PDF]

				M. Suzuki, N. Ohte, Z.-M. Wang, D. L. Williams Jr., W. C. Little, and C.-P. Cheng Altered inotropic response of endothelin-1 in cardiomyocytes from rats with isoproterenol-induced cardiomyopathy Cardiovasc Res, September 1, 1998; 39(3): 589 - 599. [Abstract] [Full Text] [PDF]

				D. D. Borgeson, J. A. Grantham, E. E. Williamson, A. Luchner, M. M. Redfield, T. J. Opgenorth, and J. C. Burnett Jr Chronic Oral Endothelin Type A Receptor Antagonism in Experimental Heart Failure Hypertension, March 1, 1998; 31(3): 766 - 770. [Abstract] [Full Text] [PDF]

				J. E. Donckier, P.-E. Massart, D. Hodeige, H. Van Mechelen, J.-P. Clozel, O. Laloux, J.-M. Ketelslegers, A. A. Charlier, and G. R. Heyndrickx Additional Hypotensive Effect of Endothelin-1 Receptor Antagonism in Hypertensive Dogs Under Angiotensin-Converting Enzyme Inhibition Circulation, August 19, 1997; 96(4): 1250 - 1256. [Abstract] [Full Text]

				J. Dupuis, D. J. Stewart, P. Cernacek, and G. Gosselin Human Pulmonary Circulation Is an Important Site for Both Clearance and Production of Endothelin-1 Circulation, October 1, 1996; 94(7): 1578 - 1584. [Abstract] [Full Text]

				J. Donckier, L. Stoleru, W. Hayashida, H. Van Mechelen, P. Selvais, L. Galanti, J.-P. Clozel, J.-M. Ketelslegers, and H. Pouleur Role of Endogenous Endothelin-1 in Experimental Renal Hypertension in Dogs Circulation, July 1, 1995; 92(1): 106 - 113. [Abstract] [Full Text]